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Abstract
Objectives: Cyclin A1 regulates cell cycle activity and proliferation in somatic and germ-line cells. Its expression increases in
G1/S phase and reaches a maximum in G2 and M phases. Altered cyclin A1 expression might contribute to clinical
symptoms in facioscapulohumeral muscular dystrophy (FSHD).
Methods: Muscle biopsies were taken from the Vastus lateralis muscle for cDNA microarray, RT-PCR, immunohistochemistry
and Western blot analyses to assess RNA and protein expression of cyclin A1 in human muscle cell lines and muscle tissue.
Muscle fibers diameter was calculated on cryosections to test for hypertrophy.
Results: cDNA microarray data showed specifically elevated cyclin A1 levels in FSHD vs. other muscular disorders such as
caveolinopathy, dysferlinopathy, four and a half LIM domains protein 1 deficiency and healthy controls. Data could be
confirmed with RT-PCR and Western blot analysis showing up-regulated cyclin A1 levels also at protein level. We found also
clear signs of hypertrophy within the Vastus lateralis muscle in FSHD-1 patients.
Conclusions: In most somatic human cell lines, cyclin A1 levels are low. Overexpression of cyclin A1 in FSHD indicates cell
cycle dysregulation in FSHD and might contribute to clinical symptoms of this disease.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an auto-
somal dominant neuromuscular disorder. It is the third most
common hereditary muscle disease with an estimated incidence of
1:20,000. FSHD usually begins in adulthood and is foremost
characterized by progressive and asymmetrical weakness and
wasting of specific muscles of the face, shoulder girdle and upper
arms, but may progress also to the lower legs [1–4]. There are two
types of FSHD: FSHD 1 (classic one) and FSHD-2. Both are
clinically identical and the only difference results from genetic
background. FSHD-1 is associated with contractions of an integral
number of 3.3 kb KpnI (D4Z4) macrosattelite repeats in the
subtelomeric region of the long arm of chromosome 4 (4q35).
D4Z4 repeats consist of 11–100 KpnI units in healthy subjects and
FSHD-2 patients, but only 1–10 KpnI units in FSHD-1 patients.
The most frequent haplotype is 4qA161 [1–5]. Recently, Lemmers
et al. reported that digenic inheritance of an SMCHD1 (encoding
structural maintenance of chromosome flexible hinge domain
containing 1) mutation and an FSHD-permissive D4Z4 allele
causes FSHD-2 [6].
FSHD is not only related to D4Z4 contractions but is also
associated with up-regulation of some genes proximal to the
deletion, including FSHD region gene 1 (FRG1) and 2 (FRG2), and
adenine nucleotide translocase-1 (ANT-1). FRG1 encodes a RNA
splicing regulator and FRG2 protein is related to RNA biogenesis.
ANT-1 is a Ca2+-dependent protein and a component of the
mitochondrial permeability transition pore (MPTP). It plays an
important role in the regulation of oxidative phosphorylation [1,3–
5,7]. Moreover, over-expression of ANT-1 as well as the deficiency
of complex III of the mitochondrial respiratory chain suggest that
FSHD is also associated with mitochondrial dysfunction [8]. Over-
expression of ANT-1 leads to the opening of mitochondrial
permeability transition pore and efflux of calcium ions from the
mitochondria leading finally to apoptosis [1–5,7–10].
Earlier studies revealed different aspects associated with FSHD
including cell cycle dysregulation [11]. Progression of cells through
the cell cycle is controlled by cyclins, a family of proteins activating
cyclin-dependent kinases (CDK). One of these cyclins, cyclin A1
(CCNA1) phosphorylates both CDK1 and CDK2, resulting in two
distinct kinase activities- one appearing in S phase, the other in G2
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- and hence regulating transition between cell cycle phases. Several
authors have shown that overexpression of CCNA1 may cause
chromatin condensation, dysregulated double strand break repair
and, consequently, apoptosis. Therefore, up-regulation of CCNA1
might lead to similar results in FSHD [12–16]. Moreover, cyclin
A1 is normally suppressed or expressed on a low level in most
somatic cells [17]. Recently, two independent research groups
have identified cell cycle dysregulation in FSHD by gene
expression profiling. Both FSHD-1 and FSHD-2 cells show
common and distinctive dysregulation in gene expression pattern
and alterations in cell cycle control. Interestingly, FSHD-1
myoblasts (when compared to healthy control cells) showed
dysregulation in cell cycle activity and proliferation processes
whereas FSHD-2 myotubes are mainly linked to dysregulated
RNA processing. Transcriptional profiles of several genes have
been also investigated in human muscle biopsies selected
according to different MRI patterns. In FSHD muscles, myopathic
and inflammatory changes are characterized by increased signals
of T2 - short tau inversion recovery (T2-STIR) sequences (also in
muscle not yet replaced by fat tissue). Normal healthy muscle does
not present elevated T2 values. Following alterations in muscle
regeneration (derived only from muscle with elevated T2 which
indicates T2-STIR hyperintensity), up-regulation of CCND1,
CCND2, CCND3, CCNA1 and CDK 4 and CDK6 and down-
regulation of CDKN1B were found [18]. In this article we present
evidence of cyclin A1 overexpression at both RNA and protein
level in FSHD-1, but not in other muscular dystrophies such as
caveolinopathy 3 (CAV 3), dysferlinopathy (DYSF) and four and a
half LIM domains protein 1 deficiency (FHL1).
Subjects and Methods
Ethics Approval
Our study was approved by the local Ethics Committee of the
Charite´ University Medicine Berlin (EA1/166/09) and written
informed consent of participants was obtained before entry into
the study.
Muscle Biopsies
Open muscle biopsies were obtained from the Vastus lateralis
muscle of seven FSHD patients and 30 control subjects (19 healthy
controls for all experiments and 11 patients with defined muscular
disorders) for microarray analysis. Healthy controls had no muscle
weakness and no evidence for neuromuscular disorders (displayed
normal creatine kinase level and normal muscle histology). Biopsy
specimens were immediately flash-frozen under cryoprotection
and then used for cryosectioning, staining, calculation of fiber
diameter area, total RNA isolation and quantitative real-time
(RT)-PCR. Cryosections were subjected to routine staining
protocols such as H&E and Gomori Trichrome.
Cell Culture
Primary myoblast cultures were isolated from fresh muscle
biopsies from seven FSHD-1 patients and from fourteen healthy
control subjects (seven of them were age-matched) as previously
described [19]. Cultures were enriched for myoblasts by magnetic
cell sorting and the use of anti-CD56 to reach at least 90% of
myoblasts (Miltenyi Biotech, Bergisch Gladbach, Germany).
Differentiation of myoblasts into myotubes was initiated at
approximately 90% confluence by switching to differentiation
medium containing DMEM (GIBCO, Darmstadt, Germany) and
2% horse serum. All experiments were carried out using cell lines
between 2 and 10 population doublings to avoid premature
replicative senescence which usually appears after 10–15 popula-
T
a
b
le
1
.
C
h
ar
ac
te
ri
za
ti
o
n
o
f
FS
H
D
-1
p
at
ie
n
ts
.
P
a
ti
e
n
t
n
u
m
b
e
r
A
g
e
in
y
e
a
rs
G
e
n
d
e
r
Ec
o
R
I+
fr
a
g
m
e
n
t
(k
b
)
Ec
o
R
I+
B
ln
I
fr
a
g
m
e
n
t
(k
b
)
M
R
C
S
(1
–
5
)
M
B
&
M
T
cu
lt
u
re
R
N
A
M
B
&
M
T
P
ro
te
in
s
(M
T
)
R
N
A
(m
u
sc
le
b
io
p
sy
)
P
ro
te
in
s
(m
u
sc
le
b
io
p
sy
)
H
y
p
e
rt
ro
p
h
y
1
2
2
M
3
4
3
1
4
+
+
+
2
+
+
2
5
4
M
3
3
3
0
4
+
+
+
+
+
2
3
4
2
M
3
2
2
9
4
+
+
+
+
+
+
4
3
7
M
2
7
2
4
4
+
+
+
2
2
+
5
6
6
F
2
7
2
4
4
+
+
2
+
2
+
6
7
2
F
3
7
3
4
4
+
+
2
2
2
2
7
5
7
F
1
5
1
2
4
+
+
2
2
2
+
N
u
m
b
e
rs
o
f
p
at
ie
n
ts
co
rr
e
sp
o
n
d
to
th
e
n
u
m
b
e
r
sh
o
w
n
o
n
th
e
p
re
se
n
te
d
W
e
st
e
rn
b
lo
t
fi
g
u
re
s.
M
R
C
S
(M
e
d
ic
al
R
e
se
ar
ch
C
o
u
n
ci
lS
ca
le
)
is
a
sy
st
e
m
fo
r
g
ra
d
in
g
m
u
sc
le
st
re
n
g
th
fr
o
m
0
to
5
.(
0
-
Z
e
ro
,1
-
T
ra
ce
,2
-
P
o
o
r,
3
-
Fa
ir
,4
-G
o
o
d
,
an
d
5
-
N
o
rm
al
).
R
N
A
w
as
is
o
la
te
d
fo
rm
m
yo
b
la
st
s
(M
B
),
m
yo
tu
b
e
s
(M
T
)
an
d
m
u
sc
le
ti
ss
u
e
.
P
ro
te
in
sa
m
p
le
s
ar
e
fr
o
m
M
T
an
d
m
u
sc
le
ti
ss
u
e
.
G
e
n
d
e
r
o
f
p
at
ie
n
ts
is
in
d
ic
at
e
d
as
‘‘m
’’
fo
r
m
al
e
an
d
‘‘f
’’
fo
r
fe
m
al
e
.
(+
)
in
d
ic
at
e
s
if
a
p
ar
am
e
te
r/
sa
m
p
le
w
as
ta
ke
n
an
d
(-
)
w
h
e
n
n
o
t.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
7
3
5
7
3
.t
0
0
1
FSHD-1 and Cyclin A1
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e73573
tion doublings [11]. Cells were collected after 3–7 days of
differentiation when about 80–90% of mononuclear myoblasts
had fused to form multinuclear elongated myotubes [19,20]. All
data regarding FSHD primary muscle cells are summarized in
Table 1.
RNA Isolation and Quantitative Real-time Reverse
Transcriptase PCR (TaqMan)
Total RNA was isolated with the Qiagen RNeasy mini kit
including the RNase-Free DNAse set (Qiagen, Hilden, Germany)
according to the instruction of the manufacturer. RNA (1 mg) was
reverse transcribed into cDNA by using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Darmstadt,
Germany) and analyzed by real-time quantitative PCR on an
ABI 7500 Fast Real-time PCR system (PE Biosystems). PCR
reactions were carried out using Taqman PCR Mastermix
(Applied Biosystems, Darmstadt, Germany) and TaqMan Gene
Expression Assays (Hs00171105_m*, Applied Biosystems, Darm-
stadt, Germany). Quantitative RT-PCR was performed as follows:
2.5 mL of master mix (2x), 0.25 mL primer assay (20x) and 1 mL
template cDNA (10 ng/ul) and 1.25 mL H20 were added to each
well. After brief centrifugation, the PCR plate was subjected to
thermocycling for 40 cycles with PCR activation at 95uC for
2 min, denaturation at 95uC for 3 seconds, and annealing/
extension at 60uC for 20 s. All samples and controls were run in
triplicates. Quantitative RT–PCR data were analyzed by the
comparative cycle number threshold method. Results are shown as
the ratio of the reference gene to target gene by using the formula:
DCt=Ct (target genes) 2 Ct (18S). To determine the relative
expression levels, we used: DDCt=DCt (FSHD) – DCt (Control).
The n-fold difference was determined by the expression 22DDCt.
RNA Isolation and Microarray
Total RNA was isolated from myotubes derived from different
cell lines for DYSF (n = 4), CAV3 (n= 4), FSHD (n= 4), FHL1
(n = 3), and healthy controls (n = 7) by using the standard TRIzol
reagent (Invitrogen, Darmstadt, Germany) according to the
manufacturer’s instructions. cDNAs were synthesized using the
Ambion’s WT expression kit (http://www.ambion.com/). Frag-
mentation and labeling was done by using the standard Affymetrix
protocol. Fragmented cDNA was hybridized for 16 h at 45uC
(Gene Chip hybridization oven 640) to the human exon array.
Arrays were washed and stained with streptavidin-phycoerythrin
in the Affymetrix Fluidics Station 450 and further scanned using
the AFFYMETRIX GeneChip Scanner 3000 7G (http://www.
affymetrix.com). The image data were analyzed with the Gene
Chip command console using Affymetrix default analysis settings.
Analysis of Expression Data
Arrays were quantile-normalized with respect to the probe GC
content using the Robust Multi-array Average (RMA) algorithm
(GC content adjustment, RMA background correction and mean
probe set summarization). No or low expressed transcripts (max.
native signal ,100) were removed. Data filtering led to a set of
25,271 meta-probe sets. Differential expression was tested by using
ANOVA followed by controlling the false discovery rate (FDR)
according to Benjamini et al. [21]. We found 59 differentially
expressed probe sets between the five sample groups (5% FDR).
The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus [22] and are accessible
through GEO series accession number GSE44874.
Immunofluorescence and Immunohistochemistry
For immunofluorescence (IF), cells were fixed 48h after seeding
with 3.7% paraformaldehyde for 20 min and then permeabilized
with 0.2% Triton X-100 for 15 min, followed by blocking with 1%
bovine serum albumin (BSA) for 30 min. Then, the primary
antibodies rabbit anti-cyclin A1 (Abcam), and mouse anti-desmin
(DAKOcytomation, Hamburg, Germany) were added and incu-
bated at room temperature for 1 h. Immunohistochemistry (IH)
was performed on 6 or 10 mm frozen sections of Vastus lateralis
muscle from eight FSHD patients and eight age-matched healthy
controls. Sections were fixed in 100% acetone for 5 min and then
blocked with 1% BSA for 30 min. Then, the primary antibodies
rabbit anti-cyclin A1 (Abcam), and mouse anti-dystrophin (C-
terminus) NCL-DYS2 (Novocastra Labolatories, Wetzlar, Ger-
many) were added and incubated at room temperature for 1 h.
For both, IF and IH, the secondary antibodies Alexa594-
conjugated anti-mouse IgG or Alexa488-conjugated anti-rabbit
IgG (Invitrogen, Cergy Pontoise, France) were added and
incubated for another 30 min. Hoechst (Sigma-Aldrich, Hamburg,
Germany) was used for 3 min to stain nuclei. Fluorescence images
were captured by using a fluorescent microscope (Leica Micro-
system LAS AF, AF 6000 Modular Systems).
Western Blot
Proteins were isolated from myotubes by solubilization in ice-
cold lysis buffer (50 mM TRIS, 150 mM NaCl, 0.5% Triton,
0.5% Na-Deoxycholate, 50 mM NaF, 1 mM Vanadate, pH=7.4,
containing protease inhibitors, complete EDTA free; Roche,
Mannheim, Germany). Protein lysates were separated with 10%
SDS-Page gel and transferred to a nitrocellulose transfer
membrane (Whatman, Dassel, Germany). The primary antibodies
for CCNA1 (BD) and b-tubulin (Abcam) were diluted in 4% milk-
powder in TBS with 0.05% Tween (TBS-T) for myotubes and 3%
BSA in TBS-T for muscle tissue and then incubated overnight at
4uC. Then, the secondary antibodies IRDYE 700 DX-conjugated
affinity purified anti-rabbit IgG (H&L) [Donkey] and IRDYE 800-
conjugated affinity purified anti-mouse IgG (H&L) [Donkey]
(Rockland) were added and incubated for another 30 min. The
signal was visualized using Odyssey Infrared Imaging System (Li-
Cor Biosciences, Bad Homburg, Germany). Calculation of
Western blots densitometry was analysed by using the Image J
analysis software (NIH).
Figure 1. Cyclin A1 expression levels in FSHD and other
myopathies (microarrays). CCNA1 Human Exon 1.0 ST Array signal
levels in FSHD (n= 4), healthy controls (n = 7), CAV3 (n = 4), DYSF (n = 4)
and FHL1 (n = 3).
doi:10.1371/journal.pone.0073573.g001
FSHD-1 and Cyclin A1
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Calculation of the Mean Myofiber Diameter
H&E-labeled 10 mm frozen cross sections derived from five
FSHD patients and five age-matched healthy controls were used to
calculate myofiber diameters as previously described by Spuler
et al. [23]. Ten images (206magnification) for each FSHD and
control subject were captured using a light microscope (Leica
Microsystems, Leica DM LB2). Thousand myofibers were chosen
to compute mean myofiber diameter. The smallest diameter of
myofiber was manually selected and calculated in mm. All
computation was done by using the Image J software (version
1.36r; Java 1.6.0_20, Maryland, USA.). To exclude/include the
probability of hypertrophy pathway activation, we performed
RNA analysis for IGF-1 (regulator of skeletal muscle size) in the
FSHD-1 and control groups, but did not find any significant
changes. Type 1 and 2 myofibers were distinguished for FSHD-1
patients and healthy controls by ATPase pH 9.4 and ATPase
pH 4.6 staining.
Statistics
RNA expression levels are presented as median, 25th and 75th
percentiles and range. Group comparisons were analyzed by using
non-parametric Mann-Whitney U and Wilcoxon’s rank tests
(GraphPad Prism version 4.0 software, San Diego, California,
USA).
For the distribution pattern of myofiber diameters (mm) of
FSHD patients and healthy controls mean values are given. At
least 10 slide fields for each examined subject were selected and
examined at a magnification 20x on a Light Microscope (Leica
Microsystems, Leica LB2). Group and subject comparisons were
analyzed by Wilcoxon test using R: A language and environment
for statistical computing (R-Version R-2.15.2, R Foundation for
Statistical Computing, Vienna, Austria) [24]. The Histogram was
made by use of ggplot2 (Version 0.9.3, Wickham et al. 2009) [25].
Statistical significance was considered at p,0.05.
Results
Cyclin A1 is Up-regulated at RNA Level in Myotubes and
Muscle Tissue from FSHD Patients
We performed microarray analysis in order to look for
differences in myotube gene expression in FSHD-1, three other
muscular disorders, and in healthy controls. Only CCNA1
(ANOVA FDR=8.761023) and LEUTX (Leucine Twenty
Homeobox, ANOVA FDR=2,11761023) RNA levels were
highly up-regulated (.28- and 50-fold, respectively) in FSHD.
Importantly, cyclin A1 RNA levels of FSHD were not only higher
compared to healthy controls but also to patients with the other
muscular disorders: CAV3, DYSF, and FHL1 (Fig. 1). RT-PCR
Figure 2. Cyclin A1 expression levels in FSHD (RT-PCR). (A) CCNA1 DCt-18S in myotubes derived from FSHD patients (n = 7) and age-matched
healthy controls (n = 7), DDCt =23.2, n-fold change: 22DDCt =9.2. Data are given as median, 25th and 75th percentiles and range. *) p,0.05; Mann-
Whitney U-test; (B) CCNA1 DCt-18S in muscle tissue derived from FSHD patients (n = 3) and age-matched healthy controls (n = 3), DDCt =21.9, n-fold
change: 22DDCt =3.7. Data are given as single values; (C) CCNA1 DCt-18S in myoblasts (MB) and myotues (MT) from healthy controls (n = 14),
DDCt = 0.3. Data are given as median; (D) CCNA1 DCt-18S in MB and MT from FSHD patients (n = 7), DDCt = 2.0. Data are given as median.
doi:10.1371/journal.pone.0073573.g002
FSHD-1 and Cyclin A1
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confirmed our findings for FSHD and controls. CCNA1 expression
was about 9-fold higher (DDCt=23.2, n-fold change:
22DDCt=9.2) in myotubes from FSHD patients (mean age 50,
n = 7) vs. age-matched controls (mean age 53, n= 7), p,0.05
(Fig. 2A). CCNA1 expression was also 3.7-fold higher
(DDCt=21.9, n-fold change: 22DDCt=3.7) in muscle tissue from
FSHD patients (mean age 55; n= 3) vs. healthy controls (mean age
54; n= 3), n.s. (Fig. 2B).
Cyclin A1 RNA Expression is Similar in Myoblasts and
Myotubes
We compared CCNA1 expression by RT-PCR between
myoblasts and myotubes and found similar cyclin A1 RNA
expression levels in myoblast and myotubes in both healthy
controls (Fig. 2C, n = 14) and FSHD patients (Fig. 2D, n = 7).
However, we noticed a large variability within the changes in
CCNA1 Ct values (myoblasts vs. myotubes) between individual cell
lines for both healthy controls and FSHD patients. In healthy
controls, there were four instances that showed .2 Ct changes,
two up and two down. In FSHD patients, one sample went from
Ct= 16 to Ct = 8 while another one went from Ct,12 to 14. In
addition, Ct values for myoblasts showed a large variability,
ranging from 12 to 20 in healthy controls and from 12 to 18 in
FSHD patients. Similar findings have been reported by Homma
et al. [26].
Cyclin A1 is Overexpressed at the Protein Level in
Myotubes and Muscle Tissue from FSHD Patients
We tested for differences in cyclin A1 expression in primary
myoblasts and myotubes derived from FSHD-1 patients and
healthy controls by using the immunofluorescence technique.
Interestingly, we observed in almost all of the stained nuclei a
positive cyclin A1 signal (cyclin A1 protein was located in the
nucleus, Fig. 3). In order to confirm that cyclin A1 is also over-
Figure 3. Immunostaining of myoblasts (MB), and myoblasts and myotubes (MB-MT). (406magnification) from one FSHD patient and one
healthy control. Desmin (red), cyclin A1 (green), Hoechst (blue) staining. Cyclin A1 was detected in nuclei of myoblasts and myotubes derived from
both FSHD patients and healthy controls.
doi:10.1371/journal.pone.0073573.g003
Figure 4. (A) Cyclin A1 protein expression (representative
Western blot) in myotubes from FSHD patients (n =4) and age-
matched healthy controls (n =4). (B) Cyclin A1 protein expression
(relative changes) in the Vastus lateralis muscle from FSHD patients and
healthy controls (data derived from A).
doi:10.1371/journal.pone.0073573.g004
FSHD-1 and Cyclin A1
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expressed at the protein level in primary myotubes, we performed
Western blot analysis and found it clearly up-regulated (.3-fold
higher) in FSHD patients (n = 4) vs. age-matched healthy controls
(n = 4) (Fig. 4A, 4B). These results could be further confirmed by
immunohistochemistry in muscle specimens of FSHD patients
(mean age 50, n= 7) and age-matched healthy controls (mean age
53, n= 7). Again, most of the myonuclei from both FSHD patients
and healthy controls stained positive for cyclin A1 but fluorescence
intensity was visually higher in patients vs. healthycontrols (Fig. 5).
In order to test that cyclin A1 is also over-expressed in muscle
tissue, we performed another Western blot analysis and found it
also up-regulated (.4-fold) in FSHD patient (n = 3) vs. age-
matched healthy controls (n = 3) (Fig. 6A, 6B).
Hypertrophy in FSHD Muscle Tissues
Muscle fiber diameter was determined on 1000 fibers each
(Vastus lateralis muscle) from FSHD patients (n = 5) and age-
matched healthy controls (n = 5). In controls, the majority of
muscle fibers had diameters between 49–59 mm which is
consistent with the average fiber diameter of Vastus lateralis in
healthy subjects calculated by Spuler et al. [23]. In FSHD
patients, we found a significant number of fibers with a diameter
.120 mm. Mean myofiber diameters were significantly different
between the two groups (p,0.001, Fig. 7, 8). No differences in
fiber diameter were found between type 1 and 2 muscle fibers.
Discussion
Cyclin A1 is highly expressed in testis and acute myeloid
leukemia where it is involved in male meiosis and cell cycle
regulation at the restriction points G1/S and G2/M. Generally,
cyclin A1 expression levels are low in most somatic cells [16,27].
Here we show that cyclin A1 is also expressed in skeletal muscle
cells lines and muscle tissue but significantly higher in FSHD
patients vs. healthy controls at both RNA and protein level.
Interestingly, both cyclin A1 and DUX4 are classified to be
epigenetically repressed in somatic cells, and DUX4-fl (a full-
length open reading frame mRNA) is known to be a germline
transcription factor specifically expressed in FSHD muscle cell
lines and muscle tissue contributing to FSHD pathophysiology
[27]. In contrast to that, Jones et al. [28] found DUX4-fl
expressed at mRNA and protein level in up to 50% of muscle
cells and biopsies derived from non-FSHD individuals meaning
that it is not sufficient to induce muscle pathology in FSHD.
In FSHD, many genes downstream to DUX4 are activated.
There are two transcripts of DUX4, the already mentioned
DUX4-fl and DUX4-s, an internally spliced form of DUX4
Figure 5. Immunostaining of cryosections of muscle tissue (406magnification) from one FSHD patient and one age-matched
control. Dystrophin (red), cyclin A1 (green), Hoechst (blue) staining.
doi:10.1371/journal.pone.0073573.g005
Figure 6. (A) Cyclin A1 protein expression (representative
Western blot) in muscle tissue from FSHD patients (n=3) and
age-matched healthy controls (n = 3). (B) Cyclin A1 protein
expression (relative changes) in the Vastus lateralis muscle from FSHD
patients and healthy controls (data derived from A)
doi:10.1371/journal.pone.0073573.g006
FSHD-1 and Cyclin A1
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mRNA. CCNA1 is downstream to both DUX4-fl and DUX4-s and
its expression is obviously 3-fold or even more increased in FSHD
patients vs. healthy controls [27]. Recently, it has been reported
that cyclin A1 is also up-regulated at RNA level in human
immortalized contracted FSHD vs. non-contracted cells [29].
Therefore, our data confirm these findings.
Due to the fact that cyclin A1 is a DUX4-induced protein its
inappropriate activation may enter cell cycle processes in the post-
mitotic muscle tissue. Interestingly, other highly differentiated
post-mitotic cells, for example adult central nervous system
neurons, keep their cell cycle in check and re-initiate it at the
risk of neurodegeneration [30]. We think a similar process might
occur in dystrophic muscle which could indicate a putative role of
Figure 7. Distribution patterns of myofiber diameters derived from FSHD patients (n=5) and age-matched healthy controls (n=5).
Diameters (mm) from 1000 myofibers each were measured in H&E-stained cross sections under a light microscope by using the Image J software.
Cumulative data are presented (FSHD: mean 71 mm, SD 23 mm; Control: mean 59 mm, SD 17 mm), p,0.001, Wilcoxon test.
doi:10.1371/journal.pone.0073573.g007
Figure 8. Cross sections of muscle fibers of (A) one FSHD patient and (B) one healthy control (206magnification, H&E-stained).
Myofiber diameter size difference indicates hypertrophy in the Vastus lateralis muscle of the patient.
doi:10.1371/journal.pone.0073573.g008
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cyclin A1 in the regeneration processes. Elevated cyclin A1 levels
lead to chromatin condensation and apoptosis in renal, ovarian
and lung carcinoma cells [31]. Therefore, cyclin A1 could be
involved in a way that it controls chromatin de-condensation
present in both FSHD-1 and FSHD-2. However, a role of cyclin
A1 as a hypothetical protein involved in chromatin formation
leaves a question mark and needs to be determined in the future.
Furthermore, apoptosis in FSHD occurs at a very low level and
cyclin A1 does not seem to play a crucial role here [32].
FSHD primary cell lines are heterogeneous and often contam-
inated with fibroblasts. In human embryonic fibroblasts, cyclin A1
is highly expressed but redundant [33]. Therefore, we studied
CCNA1 expression in muscle tissue cultures of FSHD and control
subjects and found comparable results at the RNA level. In our
microarray assays, CCNA1 expression was detectable at very low
levels in healthy controls as well as in some other myopathies such
as CAV3, DYSF and FHL1. We could confirm these data in all
FSHD patients and healthy controls by RT-PCR analyses. Even if
CCNA1 was detectable at very low levels it was still significantly up-
regulated in FSHD patients vs. healthy controls. Interestingly,
during myotubes formation, percentage of fibroblast decreased
(our own observation) leading finally to an almost pure, high-
quality culture of differentiated cells (myotubes). Furthermore,
results from RT-PCR, where total RNA was isolated from fresh
tissue biopsy, confirmed tissue culture experiment. Nevertheless,
cyclin A1 is known to be expressed in hematopoietic progenitor
cells and we cannot exclude that its increased expression in our
study derives from these cells within our biopsy samples [33,34].
Progression of FSHD along different muscles shows consider-
able differences and is obviously patient-specific. In our study, the
site of muscle biopsy was chosen for clinical reasons and usually
mildly weak muscles (grade 4– affected muscles of the 0–5 Medical
Research Council Scale [35]) were biopsied. Still, the material
used in this study was heterogeneous. Differences between FSHD
cell lines refer to different time points of myoblast growth,
expansion and myotube formation in tissue culture, well-known
among those working on FSHD. RNA expression levels of cyclin
A1 were almost similar in FSHD myoblasts and myotubes within
the same patient. Nevertheless, we observed large individual
differences of CCNA1 mRNA expression between myoblasts and
myotubes and also a large variability of Ct values in myoblasts in
both FSHD and control cell lines. This could be due to culturing
conditions commonly known in FSHD or, alternatively, an
individual variability among subjects as reported by Homma
et al. [26].
Results corresponding to the increased muscle myofiber
diameter in FSHD are ambiguous. In animal models, muscle
hypertrophy was reported and referred mainly to the increase in
muscle protein mass. In patients, pseudo-hypertrophy was
reported and attributed mainly to deposition of fat and connective
tissue [36,37]. We did not observe significant changes in IGF-1
RNA levels (data not shown) in the whole group but we found
significantly (p,0.001) increased muscle fiber diameters in FSHD-
1 patients vs. healthy controls. Magnetic resonance images could
help us to exclude/include the presence of fat and connective
tissue infiltration resulting in pseudo-hypertrophy. From our data,
we can only speculate that myofiber diameter increases in non-
affected muscles to compensate for atrophy of affected muscles in
FSHD patients.
Taken together, increased cyclin A1 protein expression could
correspond to the increase in muscle protein mass, indicating, for
example, disturbances in protein turnover finally leading to muscle
hypertrophy [38,39]. The relation between cell cycle disruption
and hypertrophy has not yet been shown in FSHD. Interestingly,
one of the ways to counteract excessive cell cycle activation is
entering the process of apoptosis [32,38–40]. Therefore, the
relation between cell cycle activation, hypertrophy and apoptosis
as processes controlling protein mass should be addressed in future
studies.
Conclusion
Cyclin A1 is overexpressed in FSHD at both RNA and protein
level. However, the functional role of cyclin A1 overexpression in
FSHD remains unknown. The relationship between up-regulated
cyclin A1 expression and disease severity and activity needs also to
be elucidated. Therefore, we will focus our attention on cyclin A1
and its possible role as a molecular biomarker and indicator of
FSHD progression.
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